Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
Open Access
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (1), 478-484
- https://doi.org/10.1159/000507320
Abstract
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare type of primary liver cancer, speculated to arise from hepatic progenitor cells, and with a worse prognosis than hepatocellular carcinoma (HCC). Serum alpha-fetoprotein (AFP) levels may be one prognostic factor. It has been suggested that checkpoint inhibition might be useful in the treatment of HCC where there is an increased expression of PD-1 and PD-L1 in the microenvironment. Its effect on CHC is unknown. We report a case with a large CHC, which was radically resected, but the 53-year-old female patient subsequently developed pulmonary metastases. Histology demonstrated low-differentiated CHC without microsatellite instability. Treatment with sorafenib was started but was stopped due to angioedema. Under subsequent gemcitabine/cisplatin treatment, the metastatic disease progressed with rising AFP levels. A third-line treatment with pembrolizumab was then started, 2 mg/kg b.w. i.v. every third week for 6 months. This resulted in a radiologically complete remission of the pulmonary metastases and AFP levels were normalized (<10 mu g/L) from a level of 1,790 mu g/L before treatment. The patient developed immune-related adverse events (AEs) including diarrhea and hepatitis. These AEs were successfully treated with prednisolone and mycophenolate mofetil, and they were eventually resolved. There are no signs of cancer recurrence neither in the liver nor in the lungs at 33 months after the start of the checkpoint inhibition treatment, and the patient is doing well. Further study is urgently needed on the role of checkpoint inhibition therapy in liver cancer.This publication has 14 references indexed in Scilit:
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitorsJournal of Hepatology, 2018
- Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumorsSurgical Oncology, 2017
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosisEuropean Journal of Cancer, 2016
- Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomographyBMC Cancer, 2016
- Combined hepatocellular cholangiocarcinoma: Controversies to be addressedWorld Journal of Gastroenterology, 2016
- Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer SyndromeThe American Journal of Surgical Pathology, 2009
- Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinomaJournal of Clinical Pathology, 2009
- Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomasJournal of Hepatology, 2004
- Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCRGastroenterology, 2002